Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases

BACKGROUND: Fingolimod (FTY), an oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS), has been associated with a significant rebound of disease activity after cessation of therapy. METHODS: We present the clinical and radiological findings of two patients with severe rebou...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Stephan, Schulten, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503590/
https://www.ncbi.nlm.nih.gov/pubmed/31105771
http://dx.doi.org/10.1177/1756286419846818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503590/
https://www.ncbi.nlm.nih.gov/pubmed/31105771
http://dx.doi.org/10.1177/1756286419846818

Ejemplares similares